Premium
Treatment experience with nonseminomatous testicular cancer in patients with stage II and stage III disease
Author(s) -
Taylor H. Grant,
Brown Archie W.,
Butler William M.,
Weltz Martin D.,
Berenberg Jeffrey L.,
McCleod David G.,
Fowler Jackson E.,
Stutzman Ray E.,
Blom Johannes
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810901)48:5<1110::aid-cncr2820480511>3.0.co;2-3
Subject(s) - medicine , bleomycin , vinblastine , testicular cancer , stage (stratigraphy) , surgery , cancer , disease , chemotherapy , gastroenterology , paleontology , biology
Thirty‐eight patients with nonseminomatous testicular cancer were treated with cis‐platinum, bleomycin, and vinblastine in combination without a prolonged maintenance phase. Twenty‐six patients with Stage III disease were treated. Seventy‐six percent of those patients treated achieved, complete remission. At a median survival time of 30 months, no patient who achieved a complete remission has relapsed. Twelve Stage II patients given adjuvant therapy remain free of disease at a median time of 23 months. Markedly elevated serum lactate dehydrogenase levels and massive disease were common findings in the patients who did not achieve complete remission. One drug death occurred secondary to sepsis. Symptoms of depression and anxiety were significant dose‐limiting factors in this group of patients.